Email this article IMMUNOBIOLOGICAL ASPECTS OF THE APPLICATION OF THE NEW METABIOTICS
- Authors: Zabokritskiy N.A.1
-
Affiliations:
- Institute of Immunology and Physiology UrB RAS
- Issue: Vol 22, No 3 (2019)
- Pages: 1150-1156
- Section: ORIGINAL ARTICLES
- Submitted: 25.08.2020
- Accepted: 25.08.2020
- Published: 15.10.2019
- URL: https://rusimmun.ru/jour/article/view/494
- DOI: https://doi.org/10.31857/S102872210007245-4
- ID: 494
Cite item
Full Text
Abstract
The paper presents the results of clinical and laboratory studies of a new metabiotic drug based on biologically active substances of the probiotic strain Bacillus subtilis B-3679. The assessment of the state and dynamics of changes in such integral immunological parameters characterizing the state of health of patients as the level of lysozyme activity and the concentration of s Ig A, and Ig A, M, G in salivary fluid of patients with chronic generalized periodontitis of moderate severity is given. It was found that the metabiotic was safe for use and had a pronounced positive clinical and therapeutic effect, normalizes the microbiocenosis of the oral cavity, which is accompanied by a decrease in the number of opportunistic microflora and an increase in the concentration of representatives of normal microflora. It was experimentally established that the studied metabiotic has a high antagonistic activity against various types of opportunistic microorganisms secreted in patients with periodontitis and promotes increased activity of salivary fluid lysozyme and immunoglobulins A and G.
About the authors
N. A. Zabokritskiy
Institute of Immunology and Physiology UrB RAS
Author for correspondence.
Email: pharmusma@rambler.ru
MD, PhD, assistant professor of the laboratory of immunophysiology and immunopharmacology,
Ekaterinburg
Russian FederationReferences
- Забокрицкий Н. А. Экспериментальная оценка коррекции гуморального иммунитета гепатопротекторным препаратом гепатобиол у лабораторных животных с острым токсическим гепатитом. Российский иммунологический журнал, 2017, 11, 2(20), 123–126.
- Забокрицкий Н. А. Оценка иммунотропного действия пробиотика бацилакт в составе трансдермальных терапевтических систем. Российский иммунологический журнал, 2017, 11, 2(20), 126– 129.
- Забокрицкий Н. А. Обоснование направлений в разработке и экспериментальном изучении новых фармакологических препаратов на основе пробиотиков и их биологически активных продуктов: автореф. дис. … д-ра. мед. наук., 2014. 3–16.
- Лабинская А. С. Микробиология с техникой микробиологических исследований. Бином, М., 2012. 72–124.
- Holzapfel W. H., Schillinger U. Introduction to preand probiotics. Food Research International 35, 2002, 109–116.
- Kailasapathy K. A., Chin J. Survival and therapeutic potential of probiotic organisms with reference to Lactobacillus acidophilus and Bifi dobacterium spp. Immunol. Cell. Biol., 2000, 78, 80–88.
- Lee Y. K., Salminen S. Handbook of Probiotics and Prebiotics. John Wiley and Sons, Ltd., 2009, 132–144. 8. Russel J., Cohn R. Probiotics. U.K., Edinburgh: LENNEX Corp. 2012, 5–58.
Supplementary files
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).